Therasly
GhostA healthcare consultancy's newsletter offering guides on biopharma strategy, covering real-world evidence after drug approval, biomarker-driven trial design, and clinical development plans for investor readiness. The writing is largely promotional and generic, with limited concrete data or original reporting.